AB Science will host a live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer - Seite 2

He is a regular reviewer for Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, and the European Journal of Cancer.

Professor Taieb is a member of the European Society for Medical Oncology (ESMO), the American Society of Clinical Oncology, and a number of French gastrointestinal cooperative groups and societies, including the PRODIGE intergroup, the Fédération Francophone de Cancérologie Digestive (FFCD), the Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) and the Société Nationale Française de Gastro-Entérologie (SNFGE). He is the founder of the AGEO French research group on GI tumours.
He has a position in the administrative council or the scientific committee of ESMO, FFCD and SNFGE. He is a member of ESMO nomination Committee since 2018.

His main research topics are non-metastatic and metastatic colon cancer and pancreatic cancer.

Particularly involved in clinical trials and translational research, Prof Taieb has led more than 10 national and international phase II and III studies and has authored 3 educational books, more than 200 peer reviewed publications and 500 meeting abstracts.

Olivier Hermine, MD, PhD
Olivier Hermine, MD, PhD is Professor of Hematology at Paris V-René Descartes University, Chief of adults Hematology staff at Hospital Necker (Paris), member of the French Académie des Sciences and author of over 700 international publications. Olivier Hermine is also co-founder of AB Science and Head of its scientific committee.

About masitinib
Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.